Claims for Patent: 8,148,076

Summary for Patent: 8,148,076

Title:	Gene expression profiling of EGFR positive cancer
Abstract:	The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
Inventor(s):	Baker; Joffre B. (Montara, CA), Cronin; Maureen T. (Los Altos, CA), Shak; Steven (Hillsborough, CA), Baselga; Jose (Barcelona, ES)
Assignee:	Genomic Health, Inc. (Redwood City, CA)
Application Number:	13/150,799
Patent Claims:	1. A method for predicting the likelihood that a human colon cancer patient will exhibit a clinically beneficial patient response to treatment with cetuximab, the method comprising: a) assaying a normalized level of an RNA transcript in a sample comprising EGFR-expressing colon cancer cells obtained from said patient, wherein the RNA transcript is the transcript of EREG; b) analyzing the normalized level of the EREG RNA transcript; and c) predicting the likelihood of response of the patient to treatment with cetuximab by comparing the normalized level of the EREG RNA transcript to gene expression data obtained from reference samples derived from patients with colon cancer, wherein an increased normalized level of the EREG RNA transcript correlates with an increased likelihood of response to treatment with cetuximab. 2. The method of claim 1, wherein said sample is a tissue sample. 3. The method of claim 2, wherein the tissue sample is fixed, paraffin-embedded, fresh, or frozen. 4. The method of claim 2, wherein the tissue sample is derived from fine needle, core, or other types of biopsy. 5. The method of claim 1, further comprising the step of preparing a report comprising a prediction of the likelihood that the patient will respond to treatment with cetuximab. 6. The method of claim 1, wherein the normalized level of the EREG RNA transcript is determined using reverse transcription polymerase chain reaction (RT-PCR). 7. The method of claim 1, wherein the normalized level of the EREG RNA transcript is determined using an array comprising polynucleotides hybridizing to a EREG gene immobilized on a solid surface. 8. The method of claim 1, wherein RNA is isolated from colon cancer cells present in a fixed, paraffin-embedded tissue by a procedure comprising: (a) incubating one or more sections of said fixed, paraffin-embedded tissue at a temperature of about 56.degree. C. to 70.degree. C. in a lysis buffer, in the presence of a protease, without prior dewaxing, to form a lysis solution; (b) cooling the lysis solution to a temperature where the paraffin solidifies, thereby generating a cooled lysis solution; and (c) isolating the RNA from said cooled lysis solution.

Details for Patent 8,148,076

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2022-11-15
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2022-11-15